Last reviewed · How we verify
AN2898 ointment, 1%
AN2898 ointment, 1% is a corticosteroid Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Treatment of mild to moderate atopic dermatitis.
AN2898 ointment is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response.
AN2898 ointment is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response. Used for Treatment of mild to moderate atopic dermatitis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AN2898 ointment, 1% |
|---|---|
| Sponsor | Pfizer |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
AN2898 ointment works by inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes, which contribute to the symptoms of inflammation and itching. This is achieved through the suppression of the immune system's response, specifically the activation of T-lymphocytes and the release of cytokines. As a result, AN2898 ointment provides relief from the symptoms of inflammation and itching associated with various skin conditions.
Approved indications
- Treatment of mild to moderate atopic dermatitis
Common side effects
- Skin atrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2898 ointment, 1% CI brief — competitive landscape report
- AN2898 ointment, 1% updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about AN2898 ointment, 1%
What is AN2898 ointment, 1%?
How does AN2898 ointment, 1% work?
What is AN2898 ointment, 1% used for?
Who makes AN2898 ointment, 1%?
What drug class is AN2898 ointment, 1% in?
What development phase is AN2898 ointment, 1% in?
What are the side effects of AN2898 ointment, 1%?
Related
- Drug class: All corticosteroid drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Treatment of mild to moderate atopic dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing